Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Intestinal FABP (FABP2) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Fatty acid-binding protein 2, Intestinal-type fatty acid-binding protein, I-FABP, FABP2, FABPI
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RD191246200R 96 wells (1 kit)
PubMed Product Details
Technical Data


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Urine


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

20 - 1280 pg/ml

Limit of Detection

3.5 pg/ml

Intra-assay (Within-Run)

n = 8, CV = 4.1%

Inter-assay (Run-to-Run)

n = 6, CV = 4.2%

Spiking Recovery


Dilution Linearity




It is intended for research use only

  • The assay time is less than 3.5 hours
  • The kit measures I-FABP in serum, plasma (EDTA, citrate, heparin) and urine
  • Assay format is 96 wells
  • Standard is recombinant protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Others, Animal studies


Intestinal fatty acid binding protein (I-FABP) or FABP-2, named after the tissue in which it was first identified, is one of the nine different FABPs characterized in mammals. The fatty acid binding proteins (FABPs) are 15 kDa cytoplasmic proteins, members of the superfamily of small intracellular lipid-binding proteins (LBPs). The primary function of all FABPs is regulation of long-chain fatty acid uptake and intracellular transport. I-FABP is a cytosolic protein specifically present in mature enterocytes at the tip of the villus of small intestine and constitutes 2% of enterocyte proteins. I-FABP has high affinity for saturated and unsaturated long-chain fatty acids, and is believed to be involved in absorption and transport of dietary fatty acids. I-FABP has two forms: alanine-containing (A54) or threonine-containing (T54) protein which display differences in binding and transporting fatty acid across cells. The I-FABP genetic polymorphism Ala54Thr was found to be associated with increased fat oxidation, insulin resistance, elevated serum leptin levels, obesity and dyslipidemia in several populations, providing additional support for I-FABP role in energy metabolism and metabolic syndrome. Serum concentration of I-FABP is low in healthy subjects, but upon enterocyte membrane integrity loss, I-FABP is released in the circulation and its serum level is rapidly increased. This makes I-FABP useful as a plasma marker for enterocyte damage and indeed, I-FABP has been promoted as a promising new serological marker for intestinal disease. Several studies have demonstrated the use of I-FABP for early detection of intestinal injury such as necrotizing enterocolitis, acute intestinal ischemia, gut wall integrity loss in viral gastroenteritis, small bowel obstruction or Crohn´s disease. Thanks to its small size, I-FABP can quickly pass through the kidney to urine, which also gives an opportunity to measure it noninvasively in urine. A recent study found serum and urinary I-FABP levels are correlated with the length of resected bowel in infants with surgical treatment of necrotizing enterocolitis.Urinary I-FABP can also distinguish necrotizing enterocolitis from sepsis in early stage of the disease.

Summary References (11)

References to Intestinal Fatty Acid Binding Protein

  • Pelsers MMAL, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, Glatz JFC: Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem 2003, 36:529-535
  • Storch J, McDermott L: Structural and functional analysis of fatty acid-binding proteins. J Lipid Res 2009, S126-S131
  • Turkovic LF, Pizent A, Dodig S, Pavlovic M, Pasalic D: FABP 2 gene polymorphism and metabolic syndrome in elderly people of Croatian descent. Bioch Medica 2012, 22(2):217-224
  • Sakamoto K, Kanda T, Bamba T, Funaoka H, Kosugi S, Yajima K, Ishikawa T: Serum intestinal fatty acid binding protein in patients with small bowel obstruction. Surg Science 2013, 4:302-307
  • Ishimura S, Furuhashi M, Watanabe Y, Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka H, Ohnishi H, Yoshida H, Saitoh S, Miura T: Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PlosOne 2013, 8(11):e81318
  • Van der Voort PHJ, Westra B, Wester JPJ, Bosman RJ, van Stijn I, Haagen IA, Loupatty FJ, Rijkenberg S: Can serum L-lactate, D-lactate, creatine kinase and I-FABP be used as diagnostic markers in critically ill patients suspected for bowel ischemia. BMC Anestesiology 2014, 14:111
  • Schurink M, Kooi EMW, Hulzebos ChV, Kox RG, Groen H, Heineman E, Bos AF, Hulscher: Intestinal fatty acid-binding protein as a diagnostic marker for complicated and uncomplicated necrotizing enterocolitis: a prospective cohort study. Plos One 2015,
  • Elnady HG, Sherif LS, Saleh MT, El-Alameey IR, Youssef MM, Shafie AIE, Helwa I, Raouf HA, EL-Taweel AN: Prediction of gut wall integrity loss in viral gastroenteritis by noninvasive marker. OA Maced J Med Sci 2015, 3(1):37-45
  • Heida FH, Hulscher JBF, Schurink M, Timmer A, Kooi EMW, Bos AF, Bruggink JLM, Kasper DC, Pones M, Benkoe T: Intestinal fatty acid-binding protein levels in necrotizing enterocolitis correlate with extent of necrotic bowel: results from multicenter study. J Pediatr Surg 2015, 50(7):1115-1118+
  • Sun DL, Cen YY, Li SM, Li WM, Lu QP, Xu PY: Accuracy of the serum intestinal fatty-acidbinding protein for diagnosis of acute intestinal ischemia: a meta-analysis. Scientific Reports 2016, 6:34371
  • Coufal S, Kokesova A, Tlaskalova-Hogenova H, Snajdauf J, Rygl M, Kverka M: Urinary intestinal fatty acid-binding protein can distinguish necrotizing enterocolitis from sepsis in early stage of the disease. J Immunol Res 2016:5727312.
Related Products Docs